Mergers: Commission approves acquisition of Actelion by Johnson & Johnson, subject to conditions

On 9 June 2017 the European Commission approved under the EU Merger Regulation the proposed acquisition of Actelion Pharmaceuticals by Johnson & Johnson. The decision is subject to conditions ensuring that clinical development of their innovative insomnia drugs will not be adversely affected by the merger.

Johnson & Johnson (United States) is active in the business sectors of consumer goods, medicines and medical devices.

Actelion (Switzerland) is active in the pharmaceutical sector and specialised in the research and development of prescription medicines and late-stage medicines in development related to a number of therapeutic areas.